Curated Information

Javascript is not enabled on this browser. This site will not work properly without Javascript.

Home

Curated Information Page

PubMed Id: 14603261

This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus^®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus^®, click here.

Wan X, Helman LJ (2003) Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells. Oncogene 22, 8205-11 14603261

Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.

T308-p - Akt1 (human)

▲

Orthologous residues

Akt1 (human): T308‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p

Characterization

Methods used to characterize site in vivo: phospho-antibody, western blotting

Disease tissue studied: rhabdomyosarcoma

Relevant cell lines - cell types - tissues: C2C12 (myoblast), Rh13 (muscle cell), Rh18 (muscle cell), Rh30 (muscle cell), Rh4 (muscle cell), Rh5 (muscle cell)

Cellular systems studied: cell lines

Species studied: human, mouse

Upstream Regulation

Treatments, proteins and their effect on site modification:

Treatments	Referenced Treatments	Effect
IGF-2		increase
wortmannin	IGF-2	inhibit treatment-induced increase
wortmannin		decrease

S473-p - Akt1 (human)

▲